title: Cancer drug development using glucose metabolism radiopharmaceuticals.
abstract: Imaging of glucose metabolism has resulted in significant improvements in staging and follow-up in oncology. (18)F-FDG PET has become a routine clinical test for most solid tumours. Several radionuclide-labeled derivatives of deoxyglucose that have shown that glucose metabolic imaging may be a useful tool for improving tumour staging, restaging, and monitoring of tumour response to therapy.
authors.affiliation: Department of Nuclear Medicine, Affiliated Hospital, Luzhou Medical College, Luzhou, Sichuan, China.
authors.forename: Y Y
authors.initials: YY
authors.lastname: Sun
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015195:Drug Design; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D009367:Neoplasm Staging; D009369:Neoplasms / Q000175:diagnosis* / Q000628:therapy; D049268:Positron-Emission Tomography / Q000379:methods; D019275:Radiopharmaceuticals; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D005947:Glucose